SEPTInvestingStart Free

KROS 8-K: SEC filing

Keros Therapeutics

Filed with the SEC on · accession 0001664710-26-000065

KROS filed a 8-K (current report) with the SEC on Nov 5, 2026. Keros Therapeutics reported Q3 2026 financial results with net income of $14.2 million (vs. a $7.3 million net loss in Q3 2025), driven by revenue from its Takeda license agreement, and provided pipeline updates including first patient dosed in a Phase 2 DMD trial of rinvatercept and nomination of… The stock moved -12.7% by the first close after the filing.

Summary of the filing

Keros Therapeutics reported Q3 2026 financial results with net income of $14.2 million (vs. a $7.3 million net loss in Q3 2025), driven by revenue from its Takeda license agreement, and provided pipeline updates including first patient dosed in a Phase 2 DMD trial of rinvatercept and nomination of KER-206. The company reported $259.5 million in cash and expects its runway to extend into the second half of 2028.

For details, click here →How to read a 8-K →

Key details

Q3 2026 net income$14.2M
Q3 2025 net loss-$7.3M
Q3 2026 research and development expenses$20.5M
Q3 2025 research and development expenses$19.5M
Q3 2026 general and administrative expenses$6.7M
Q3 2025 general and administrative expenses$10.1M
Cash and cash equivalents as of September 30, 2026$259.5M
Cash and cash equivalents as of December 31, 2025$287.4M
IssuerKeros Therapeutics, Inc.
License agreement partnerTakeda
President and chief executive officerJasbir S. Seehra, Ph.D.

How KROS stock reacted

Close before

$10.83

Nov 4, 2026

First close after

-12.74%

$9.45

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for KROS, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for KROS?

Click here

Frequently asked questions

What did KROS file with the SEC on Nov 5, 2026?

KROS filed a 8-K (SEC filing). Keros Therapeutics reported Q3 2026 financial results with net income of $14.2 million (vs. a $7.3 million net loss in Q3 2025), driven by revenue from its Takeda license agreement, and provided pipeline updates including first patient dosed in a Phase 2 DMD trial of rinvatercept and nomination of KER-206. The company reported $259.5 million in cash and expects its runway to extend into the second half of 2028.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

How did KROS stock react to this filing?

KROS closed at $10.83 before the filing and $9.45 on Nov 5, 2026 (-12.74%).

Other KROS SEC filings

Get alerts when KROS files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
KROS overviewKROS analysisKROS newsLatest SEC filings